This website is available in:
To change websites, find a country in the A - Z list then choose a language.
To change websites, click on the map pins to find a country then choose a language.
HomeLife SciencesBiopharmaceutical ServicesClinical Research ServicesClinical PharmacologyExploratory Clinical Trials
When you need to demonstrate the human relevance of preclinical pharmacology, you need a partner with proven clinical trial experience. We offer an exploratory IND study approach to minimize preclinical and clinical investment, administering limited exposure doses predicted to elicit pharmacology, without safety issues. By using our trusted, tested approach, you will uncover important information such as an assessment of the mechanism of action in humans, and pharmacokinetics and interaction with a particular therapeutic target.
Our exploratory trial management includes:
Our clinical facility is fully authorized for C14 and to conduct AMS microdosing trials. Within SGS’s infrastructure, we can prepare and formulate C14 radiolabeled compounds under full GMP control. Also, for PET microdosing studies, specialized contracted laboratory facilities have a cyclotron for producing radionuclide and are certified for radionuclide labeled drug synthesis.
SGS has been working in early compound development for many years. Over that time, we have gained unique expertise in early proof of concept clinical trials in the following areas:
Biochemical markers can efficiently support the clinical trial assessment of drug candidates during Phase I, Phase II and Phase III trials.
Our GLP accredited immunoanalysis laboratory can offer you validated immunoassays for a number of biochemical markers. Thanks to our policy of expansion and improvement, the list of assays available is constantly being updated and covers a wide variety of therapeutic areas.
Contact SGS today to learn how we can help with your early phase exploratory clinical trials.